Instituto de Química Médica (IQM, CSIC), Juan de la Cierva 3, E-28006 Madrid, Spain.
Centro de Investigaciones Biológicas (CIB, CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain.
Eur J Med Chem. 2018 Mar 25;148:337-348. doi: 10.1016/j.ejmech.2018.02.019. Epub 2018 Feb 10.
Based on the conformation of the α-methyl chalcone TUB091 in its complex with tubulin, a series of conformational mimetics have been designed and synthesized where the methyl group of the chalcone has been fused to phenyl ring B resulting in 1,2,3,4-tetrahydronaphthalen-2-yl aryl ketones. Among the synthesized compounds, the 5-amino-6-methoxy derivative, with a similar substitution pattern to that of TUB091, showed antiproliferative activity around 20 nM against tumor and endothelial cells. Tubulin binding experiments confirmed its binding to tubulin at the colchicine site with a Kb of 2.4 × 10 M resulting in the inhibition of the in vitro assembly of purified tubulin. Moreover, based on the recently reported complex of combretastatin A4 (CA4) with tubulin, a comparative analysis of the binding mode of CA4 and the α-methyl chalcone to tubulin has been performed.
基于 α-甲基查耳酮 TUB091 与微管蛋白复合物的构象,设计并合成了一系列构象类似物,其中查耳酮的甲基与苯环 B 融合,得到 1,2,3,4-四氢萘-2-基芳基酮。在所合成的化合物中,具有与 TUB091 相似取代模式的 5-氨基-6-甲氧基衍生物对肿瘤和内皮细胞表现出约 20 nM 的抗增殖活性。微管蛋白结合实验证实,它与微管蛋白在秋水仙碱结合位点结合,Kb 为 2.4 × 10 M,导致纯化的微管蛋白体外组装的抑制。此外,基于最近报道的 combretastatin A4(CA4)与微管蛋白的复合物,对 CA4 和 α-甲基查耳酮与微管蛋白的结合模式进行了比较分析。